What Your Healthcare Facility Needs to Know about Nozin Nasal Sanitizer

March 22, 2015

Nozin® Nasal Sanitizer® antiseptic is clinically proven to provide reduction of Staph aureus nasal carriage.

Nozin® Nasal Sanitizer® is an advanced antiseptic and a new approach for hospitals that are taking steps to help reduce the risk of the transmission of pathogens, such as Staph aureus.  Helath professionals regard Nozin® Nasal Sanitizer® as an innovation in infection control - Think Hand Sanitizer for Your Nose®.

Health concerns regarding the spread of microbial infections are driving a new level of awareness. Nozin is at the forefront of providing safe and effective solutions to address this critical area for the purpose of improving safety and helping reduce the overall risk of infection.  Since Nozin Nasal Sanitizer is an antiseptic and nonantibiotic,  antibiotic resistance build up is not a concern.  The product can be used multiple times daily by staff and patients.

A major article on the clinical study that tested Nozin Nasal Sanitizer® has been published in the August 2014 issue of the American Journal Of Infection Control. The conclusion in the peer reviewed study included the observation that the ability of Nozin Nasal Sanitizer to reduce nasal bacteria carriage suggested  "the usefulness of this approach as a safe, effective, and convenient alternative to antibiotic treatment."

Nozin Nasal Sanitizer® Nozaseptin® formula is a patented compounding of ethanol and natural, moistruizing emollients that is clinically shown to be effective at reducing nasal bacteria colonization.

Patients with Staph aureus infections incur more than three times the cost of other patients.  Staph aureus infections cost more than $14.5 billion annually to treat while the cost for all hospital acquired infections is $30.5 billion. (HospitalInfection.org)

Nozin protocols offer a simple and economical solution to facilities and hospitals in several areas:

Post-Operative Care:  Nozin Nasal Sanitizer® may be used for the post-operative phase of recovery when the patient is still at risk for pathogens transferred from other areas of their body, their healthcare staff or visitors.  Nozin Nasal Sanitizer® can help to reduce the environmental burden from pathogens such as Staph aureus that reside in the nares.

Screen and Isolate Patients:  Screening high-risk patients coming into the facility or hospital and then isolating them depending on the results is costly.  We propose proper swabbing with Nozin Nasal Sanitizer of all high-risk patients entering the facility on arrival, in their room, and then at each shift to replace the need to isolate. Nozin Nasal Sanitizer® reduces Staph aureus carriage with proper use and application..  This can save facilities time and money and, since Nozin Nasal Sanitizer is not an antibiotic, antibiotic stewardship guidelines are supported.

High Risk Populations:  Patients that are immuno-suppressed; patients with chronic diseases; newborns, infants and children; and other patient populations that may be classified as high risk are vulnerable to multiple infection control issues.  Nozin Nasal Sanitizer provides another layer of protection for the patient and/or healthcare professional to help reduce risk.

Nozin would like you to be a Partner in Prevention in promoting this infection control innovation, safely, simply, and cost-effectively.

Health Professionals:
Request a comprehensive analysis of your colonization risk mitigation protocols today.

© 2004-2023 Global Life Technologies Corp. All rights reserved. All trademarks are property of their respective owners. Nozin® Nasal Sanitizer® antiseptic is an OTC topical antiseptic drug and no claim is made that it has an effect on any specific disease. | Patent Nos.